Pfizer and BioNTech abruptly ended a clinical trial for their COVID vaccine in healthy adults aged 50 to 64 after enrollment fell far short of what the companies needed to generate usable data. The cancellation, disclosed in a March 30 letter to trial investigators, marks the latest sign that the American public has moved on from the mRNA vaccine campaign, and that the pharmaceutical giants behind it are feeling the consequences.
The companies told investigators they were well below the 25,000 to 30,000 participants required, Just the News reported. Reuters, which viewed the letter, said Friday was the last day Pfizer had been scheduled to monitor trial participants for signs of COVID illness. Two sources from companies managing 9 percent of trial sites told Reuters that Pfizer had instructed them in writing weeks earlier to stop recruiting.
Pfizer and BioNTech insisted the cancellation had nothing to do with safety. "This study is not ending as a result of any safety or benefit-risk concerns," the companies said, attributing the decision to an "inability to generate relevant post-marketing data" with lagging enrollment. They said they had already informed the Food and Drug Administration.
The FDA did not respond to a query from Just the News.
The enrollment failure did not happen in a vacuum. Only about 18 percent of American adults continue to take COVID vaccines, with roughly half that rate among children, based on CDC data. A plurality of adults, 48 percent, told surveyors they "probably or definitely" won't get a vaccine this season. Among parents of children, 60 percent said the same.
The screening numbers were even more damaging. A trial contractor executive told Reuters that more than 80 percent of initial participants "fail at pre-screening because they don't meet the health criteria." So not only were few people volunteering, most of those who did could not even qualify.
Moderna faces the same headwinds. Sources at four trial sites told Reuters that Moderna was also struggling to hit 30,000 enrollment for its own COVID vaccine candidate targeting the same age group. Yet Wall Street barely flinched. Pfizer and Moderna shares rose nearly 1 percent, and BioNTech's climbed about 2 percent after the news broke.
Jeffrey Tucker, president of the Brownstone Institute, framed the cancellation bluntly on X:
"Essentially, the market itself is taking the Covid shots off the market. It amounts to a humiliating repudiation of one of history's largest and most destructive inoculation attempts."
The Vaccine Research Safety Foundation, led by onetime Democratic presidential candidate funder Steve Kirsch, described the falling vaccination rate as "a massive, nationwide recalibration of risk-benefit" and called the aborted trial a sign of "trust erosion." The foundation posted an image depicting Pfizer as the Titanic striking an iceberg labeled "public skepticism" and "data transparency."
The backdrop to this enrollment collapse is a significant shift at the FDA itself. Commissioner Marty Makary and Vinay Prasad of the Center for Biologics Evaluation and Research published a warning to vaccine makers in the New England Journal of Medicine: placebo-controlled clinical trials would be required for COVID boosters aimed at people under 65. That requirement was a sharp departure from the previous approach, where boosters sailed through with minimal independent testing.
Prasad told agency staff last fall that approval requirements would tighten further after the agency identified at least 10 children who died "after and because of" receiving a COVID vaccine. That disclosure alone raised questions about what federal health officials knew and when, and how aggressively they pursued the truth during the years of mass vaccination campaigns.
The contrast with Prasad's predecessor, Peter Marks, is instructive. In 2022, Marks agreed not to reject a vaccine for children under 5 "solely" because it was less than 50 percent effective. That standard, or lack of one, reflected a broader pattern of institutional leniency that critics say eroded public confidence in the regulatory process.
Sociologist Josh Guetzkow raised a different concern on X, suggesting the trial cancellation itself might be strategic. He wrote that he "would not be surprised if this is a ruse to force the FDA to rescind its rule requiring trials for new COVID boosters." Guetzkow also noted that Prasad was scheduled to leave the agency at month's end, raising the possibility that the new trial requirements could be reversed once their chief advocate departs.
The pressure on Pfizer is not limited to American enrollment numbers. Across the Atlantic, Helmut Sterz, Pfizer Europe's chief toxicologist until 2008, told a German pandemic inquiry that the "carcinogenic risk" from mRNA shots "was not investigated due to time constraints." Sterz added that standards lagged in a study on "reproduction, fertility, pregnancy and newborn development," and that there were "no reliable estimates" on those fronts. GBNews reported his testimony.
Back in the United States, clinical trial whistleblower Brook Jackson's False Claims Act lawsuit against Pfizer remains active. The 5th U.S. Circuit Court of Appeals heard arguments in December. Jackson wrote on X Thursday that the court is expected to rule "any Friday now."
Jackson posed a pointed question: "You can't certify a lie. So what is an FDA authorization built on fraud?"
The legal and political landscape around the case has shifted. Just the News reported that Attorney General Pam Bondi, before being fired last week, was attempting to undermine Jackson's lawsuit. The case's outcome could have far-reaching implications for how the federal government handles pharmaceutical fraud claims, and for the broader question of whether the public was given honest information about these vaccines from the start.
The public's growing skepticism did not emerge from nowhere. It was fed, in part, by the government's own resistance to disclosure. A federal judge rejected the FDA's proposal to release Pfizer vaccine licensing documents at a pace of just 500 pages per month, a schedule that would have pushed full disclosure to 2097. Judge Mark Pittman instead ordered the agency to release 55,000 pages every 30 days, making roughly 450,000 pages of records available by the end of September.
"There may not be a more important issue at the Food and Drug Administration... than the pandemic, the Pfizer vaccine... and making sure that the American public is assured that this was not rush[ed] on behalf of the United States," Judge Pittman wrote. He quoted Senator John McCain: "Excessive secrecy from a government agency feeds conspiracy theories and reduces the public's confidence in the government."
That secrecy took a measurable toll. Pfizer's own spring 2021 analysis of "post-authorization adverse event reports" for the FDA ran to nearly nine pages of single-spaced "adverse events of special interest." When documents like that are locked away for decades, the public pays the price, not just in dollars, but in trust.
The World Health Organization effectively declared an end to the pandemic in May 2023. Yet federal health officials continued pushing boosters with minimal independent evidence of benefit for younger, healthy populations. Then-CDC Director Rochelle Walensky initially claimed the vaccines stopped transmission, a claim the CDC's own data undercut.
Pfizer, for its part, is not retreating from the vaccine business entirely. The company is planning to seek regulatory approval for a Lyme vaccine developed with partner Valneva. But the COVID chapter, the one that generated billions in revenue and raised fundamental questions about government accountability, is closing on terms Pfizer did not choose.
Several open questions remain. How many participants had actually enrolled before the plug was pulled? What did the FDA communicate back to Pfizer after being notified? Will Moderna's parallel trial suffer the same fate? And will the FDA's new clinical trial requirements survive Prasad's expected departure?
The answers matter. But the enrollment numbers already tell a story that no press release can rewrite. When a pharmaceutical giant cannot find 25,000 healthy adults willing to participate in a vaccine trial, for a product that was once marketed as a civic duty, the public has rendered its own verdict.
Institutions that spent years dismissing legitimate safety questions, suppressing documents, and shaming dissenters are now watching the consequences arrive. Not through regulation. Not through legislation. Through the simple, quiet refusal of millions of Americans to line up again.
